barinthuslogo.jpg
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
15 nov. 2024 11h02 HE | Barinthus Biotherapeutics
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
barinthuslogo.jpg
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
15 nov. 2024 11h01 HE | Barinthus Biotherapeutics
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with
barinthuslogo.jpg
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
01 oct. 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
MDHSS-logo_horizontal.png
Hepatitis: The silent killer May is Hepatitis Awareness Month, the perfect time for individuals to talk to their health care providers about hepatitis vaccinations.
Black-Enochian-Primary-Logo.jpg
Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
12 oct. 2021 18h00 HE | Enochian BioSciences, Inc.
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
EnochianLogo-2000x1607px.jpg
Enochian Biosciences Acquires an Exclusive License for a Novel Hepatitis B Virus Potential Treatment or Cure
03 févr. 2020 07h30 HE | Enochian Biosciences, Inc.
LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the...
EnochianLogo-2000x1607px.jpg
Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus
10 déc. 2019 07h00 HE | Enochian Biosciences, Inc.
A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells.  Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect...
OnCore Biopharma, Inc.
OnCore Biopharma Announces Exclusive HBV Research Collaboration With the Baruch S. Blumberg Institute
19 nov. 2014 07h00 HE | OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biopharmaceutical company focused on the research, development and commercialization of oral...